HealthCo Healthcare and Wellness (HCW) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
3 Jun, 2026Executive summary
Achieved 5% year-over-year growth in FFO per unit and DPU for 1H FY25, both at 4.2 cents, with a diversified $1.6 billion healthcare real estate portfolio focused on stable, growing distributions and long-term capital growth.
Maintained 99% occupancy and 100% cash rent collection, with 79% of leases CPI-linked and a weighted average lease expiry of 11.6 years.
Asset valuations remained stable as of December 2024, with a 0.8% gross increase from June 2024.
Portfolio reduced from 25 to 20 properties due to asset recycling, with $46.5 million in property sales between July and November 2024.
Healthscope assets represent a significant portion of earnings; ongoing market speculation and unit price volatility are acknowledged, with contingency plans and governance in place to protect value.
Financial highlights
1H FY25 FFO: $23.5m, up from $22.6m in 1H FY24, with DPU of 4.2 cents per unit; 100% of distribution covered by FFO.
EBITDA: $34.7m in 1H FY25, up from $34.2m in 1H FY24.
Net loss widened to $15.3 million for the half-year ended 31 December 2024, compared to $5.1 million loss in the prior year period.
Asset recycling program resulted in $47 million of asset sales at around a 5% discount to book value, with an average yield just under 5.5%.
Net tangible assets per unit at $1.58 as of Dec-24.
Outlook and guidance
FY25 FFO per unit and DPU guidance reaffirmed at 8.4 cents, predicated on continued rent payments and portfolio performance.
No significant post-31 December 2024 events expected to affect future operations or financial position.
Management remains confident in the private hospital asset class and long-term value creation.
Latest events from HealthCo Healthcare and Wellness
- 16% FFO per unit growth, 99% occupancy, and 5% FY25 guidance highlight strong performance.HCW
H2 20243 Jun 2026 - Receivership of a major tenant impacted results, but portfolio resilience and liquidity remain strong.HCW
H2 20253 Jun 2026 - Distributions paused amid Healthscope uncertainty, but portfolio remains resilient and well-capitalized.HCW
H1 20263 Jun 2026